Olympus Taps Global MedTech Veteran Michael Parenti as Next CFO

Olympus ( (JP:7733) ) has provided an update.

Olympus has announced a planned change in its top finance leadership, with Michael Parenti set to become Executive Officer and Chief Financial Officer effective April 1, 2026, pending formal board approval in March. The move is part of a succession plan aimed at strengthening the company’s management structure and enhancing its financial management capabilities.

Parenti brings broad experience from senior finance roles at global MedTech and healthcare companies, including CFO positions in China and Japan for Johnson & Johnson and a group CFO role at Stryker. Olympus expects his global perspective and track record in complex, multicultural environments to support disciplined capital allocation, sustainable growth, and value creation, as the company reshapes its executive team under CEO Bob White.

The appointment will see current CFO Tatsuya Izumi step down from his role as Executive Officer and Chief Financial Officer. From April 1, 2026, Olympus’s management team will include Parenti as CFO alongside other function and division heads, reinforcing a globally oriented leadership bench in areas such as strategy, technology, manufacturing, and quality.

The most recent analyst rating on (JP:7733) stock is a Hold with a Yen2140.00 price target. To see the full list of analyst forecasts on Olympus stock, see the JP:7733 Stock Forecast page.

More about Olympus

Olympus Corporation is a Japan-originated global MedTech company listed on the Tokyo Stock Exchange Prime Market, known for its medical technology and healthcare solutions. The company focuses on gastrointestinal, surgical and interventional solutions, leveraging advanced imaging and device technologies to serve healthcare providers worldwide.

Average Trading Volume: 3,069,606

Technical Sentiment Signal: Hold

Current Market Cap: Yen2174.2B

For detailed information about 7733 stock, go to TipRanks’ Stock Analysis page.